{"id":"https://openalex.org/W2355096464","doi":null,"title":"Recent Report on Cardiovascular Safety of Cox-2 Inhibitor Celebrex","display_name":"Recent Report on Cardiovascular Safety of Cox-2 Inhibitor Celebrex","publication_year":2005,"publication_date":"2005-01-01","ids":{"openalex":"https://openalex.org/W2355096464","mag":"2355096464"},"language":"en","primary_location":{"id":"mag:2355096464","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZZXZ200501002.htm","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109296786","display_name":"Hu Da","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Hu Da","raw_affiliation_strings":["yi"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"yi","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5109296786"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.27556512,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/celecoxib","display_name":"celecoxib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/naproxen","display_name":"naproxen","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cox-2-inhibitors","display_name":"COX-2 inhibitors","score":0.8700000047683716},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.9750000238418579},{"id":"https://openalex.org/keywords/adverse-cardiovascular-events","display_name":"cardiovascular adverse events","score":0.8169999718666077},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C2776467144","wikidata":"https://www.wikidata.org/wiki/Q408801","display_name":"Celecoxib","level":2,"score":0.9757089614868164},{"id":"https://openalex.org/C2778115740","wikidata":"https://www.wikidata.org/wiki/Q1215575","display_name":"Naproxen","level":3,"score":0.9182335138320923},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.7710063457489014},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7086181640625},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6087755560874939},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6076017618179321},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5073274970054626},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40446358919143677},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34609678387641907},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29202377796173096},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.21248772740364075},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2355096464","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZZXZ200501002.htm","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2084363614","https://openalex.org/W7100649956","https://openalex.org/W2622046502","https://openalex.org/W2556825373","https://openalex.org/W4239482872","https://openalex.org/W2292950212","https://openalex.org/W4251861025","https://openalex.org/W2071690120","https://openalex.org/W2408767050","https://openalex.org/W4243141012"],"abstract_inverted_index":{"Food":[0],"and":[1,14,27,76],"Drug":[2],"Administration":[3],"(FDA)":[4],"has":[5],"suspended":[6],"the":[7,32,50,57,60],"use":[8],"of":[9,34],"both":[10],"celecoxib":[11,26,67],"(Celebrex\ue617,":[12],"Pfizer)":[13],"naproxen":[15,28,52],"(Aleve\ue617,":[16],"Bayer)":[17],"in":[18],"prevention":[19],"large":[20],"clinical":[21],"trials":[22],"after":[23],"discovering":[24],"that":[25,64],"appeared":[29],"to":[30,54,66],"increase":[31],"risk":[33],"cardiovascular":[35,79],"events":[36],"with":[37],"patients":[38,44],"on":[39,59,72],"placebo.":[40],"FDA":[41],"also":[42],"advises":[43],"who":[45],"are":[46],"currently":[47],"taking":[48],"over":[49],"counter":[51],"products":[53],"carefully":[55],"follow":[56],"instructions":[58],"label.":[61],"Pfizer":[62],"suggested":[63],"alternatives":[65],"should":[68],"be":[69],"considered":[70],"based":[71],"individual":[73],"patient":[74],"needs":[75],"risk.":[77],"The":[78],"community":[80],"responds":[81],"differently.":[82]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}